Clinton calls on hedge fund manager to return drug to original price

Published 09/28/2015, 02:19 PM
Updated 09/28/2015, 02:28 PM
© Reuters. U.S. Democratic presidential candidate Hillary Clinton answers questions from the audience following a speech in the gymnasium of Moulton Elementary School in Des Moines
META
-

WASHINGTON (Reuters) - Democratic presidential candidate Hillary Clinton on Monday called on Turing Pharmaceuticals to roll back the price of the anti-infective drug Daraprim to what it was when it was purchased by the small pharmaceutical company.

Clinton, taking questions on Facebook (NASDAQ:FB), called on Turing and its Chief Executive Officer Martin Shkreli to lower the cost of the 62-year-old treatment for a dangerous parasitic infection.

"What's it going to be? Do the right thing. Lower the cost today to its original price," Clinton wrote.

© Reuters. U.S. Democratic presidential candidate Hillary Clinton answers questions from the audience following a speech in the gymnasium of Moulton Elementary School in Des Moines

Turing, after generating outrage last week by the fact it raised the cost of Daraprim to $750 from $13.50 per pill, has said it would roll back the price but has not named a figure.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.